The epidermal growth factor receptor, or EGFR, is found at abnormally high levels on the surface of many types of cancer cells. The study, led by Dr. Beth Levine and published Sept. 12 in Cell, revealed that EGFR turns off autophagy, a process by which cells recycle unneeded parts, by binding to a protein, Beclin 1, which normally turns on the process.
The researchers found that the deactivation of autophagy by EGFR led to more rapid tumor growth and chemotherapy resistance in mice implanted with non-small lung carcinoma cells.
“The fact that this type of cell surface receptor can directly interact with Beclin 1 and shut off autophagy provides fundamental insight into how certain oncogenes may cause cancer,” said Dr. Levine, director of the Center for Autophagy Research and a Howard Hughes Medical Institute (HHMI) investigator at UT Southwestern. “Our findings suggest that inactivation of autophagy may be a critically important factor in the progression of lung cancer.”
Earlier work in the laboratory of Dr. Levine identified beclin 1 as the first mammalian gene shown to function in autophagy. Defects in this gene may contribute not only to cancer, but also to aging, neurodegenerative diseases, and infectious diseases.
While the link between EGFR cell signaling action and cancer growth was known, with several pharmaceutical inhibitors of EGFR already on the market to combat cancer, exactly how this process worked was a mystery. This latest research uncovers Beclin 1 inactivation as one important way in which EGFR may derail the body’s cancer-fighting autophagy machinery to increase tumor growth.
A second finding in the new study related to chemotherapy resistance. Several clinical trials are currently ongoing to test inhibitors of autophagy as a means of overcoming the resistance to chemotherapeutic drugs that many tumors develop. Unexpectedly, Dr. Levine’s study found just the opposite: that autophagy inhibition may actually worsen chemotherapy outcomes for patients with specific cancer mutations. The researchers showed that cancer cells with reduced autophagy grew faster and were more resistant to chemotherapy than cancer cells with normal autophagy. Dr. Levine noted that these findings may apply to many different types of cancers, especially those that rely on EGFR (or related signaling molecules) for their rapid growth.
About 10 percent of lung cancer patients have mutations in the EGFR oncogene, according to Dr. John Minna, one of the study authors and Director of the Nancy B. and Jack L. Hamon Center for Therapeutic Oncology Research and the W.A. “Tex” and Deborah Moncrief Jr. Center for Cancer Genetics at UT Southwestern. For those patients in particular, this finding could have significant impact in developing a personalized, targeted therapy.
“The EGFR protein is one of our most important targets for lung cancer therapy – especially in patients whose tumors have certain EGFR gene mutations,” Dr. Minna said. “We have oral medications that achieve dramatic clinical benefit and increase survival in this subset of patients, but even these successfully treated patients eventually become resistant to the treatment.
“These new findings are important for two reasons: First, they provide insight into how to extend EGFR-targeted therapy to a much larger group of lung cancer patients, including those whose tumors do not have mutations. Second, they provide a totally new approach to overcoming resistance to EGFR-targeted therapy.”
Other UT Southwestern researchers involved in the study were lead author Dr. Yongjie Wei, assistant professor of internal medicine; Zhongju Zou, HHMI research specialist; Dr. Nils Becker, a former research assistant in internal medicine; Dr. Matthew Anderson, a former postdoctoral researcher in internal medicine; Dr. Rhea Sumpter, instructor of internal medicine; Dr. Guanghua Xiao, associate professor of clinical sciences; Dr. Lisa Kinch, bioinformatics scientist in biochemistry; Dr. Prasad Koduru, professor of pathology; Dr. Nick Grishin, professor of biophysics and biochemistry and an HHMI investigator; and Dr. Michael Peyton, a senior research scientist in the Hamon Center for Therapeutic Oncology Research. Researchers from Johns Hopkins University School of Medicine and Columbia University Medical Center also participated.
The research was supported by three grants from the National Institutes of Health, including a Lung Cancer SPORE (Specialized Program of Research Excellence) grant from the National Cancer Institute.
About UT Southwestern Medical Center
UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has many distinguished members, including five who have been awarded Nobel Prizes since 1985. Numbering more than 2,700, the faculty is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 90,000 hospitalized patients and oversee more than 1.9 million outpatient visits a year.
This news release is available on our home page at utsouthwestern.edu/home/news/index.html
To automatically receive news releases from UT Southwestern via email, subscribe at UT Southwestern.edu/receivenews
Debbie Bolles | New
Further reports about: > Interference > Medical Wellness > Recycling > cancer cells > cellular protein > chemotherapeutic drug > chemotherapy resistance > degenerative disease > gene mutation > lung cancer > lung cancer patients > neurodegenerative disease > signaling molecule > therapeutic > tumor growth > types of cancer
What the world's tiniest 'monster truck' reveals
23.08.2017 | American Chemical Society
23.08.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
23.08.2017 | Materials Sciences
23.08.2017 | Automotive Engineering
23.08.2017 | Life Sciences